David McMillan, PhD

David McMillian





Research Interests
Representative Publications
Biographical Information

Associate Professor

Durham Research Center 3050
985800 Nebraska Medical Center
Omaha, NE 68198-5800

E-mail: dcmcmillan@unmc.edu

Research Interests:

My general area of research interest is in mechanisms of toxicity of drugs and environmental chemicals. More specifically, I am interested in the mechanism underlying pro-oxidant drug-induced hemolytic anemia and in the metabolism and toxicity of the environmental contaminant, trichloroethylene.

In regards to hemolytic anemia, I have worked to understand how redox-active metabolites of certain drugs cause oxidative damage within erythrocytes and how this damage commits the red cells to premature sequestration and phagocytosis by macrophages in the spleen. This toxicity is especially severe in patients with a genetic deficiency in erythrocytic glucose-6-phosphate dehydrogenase (G6PD) activity; these individuals are unable to maintain adequate levels of NADPH in response to oxidative stress. Certain drugs, such as the antimalarial agent, primaquine, are contraindicated in G6PD-deficiency, and part of my research has been directed towards the rational re-design of this drug so that it can be used safely in these patients.

In regards to education, I am interested in developing innovative web-based teaching methods in pharmacology that can be customized to fit the needs of different types of students who are obtaining professional degrees in the biomedical sciences. To provide a mechanism for this effort, I am participating in UNMC’s Instructional Technology Scholars Program. My long-range plans in this program are to develop an on-line pharmacology course for physical therapy students and evaluate its effectiveness using current qualitative methodology.

Representative Publications:

  1. McMillan, J.M. and McMillan, D.C. (2006). S-Adenosylmethionine but not glutathione protects against galactosamine-induced cytotoxicity in rat hepatocyte cultures. Toxicology 22, 175-184.
  2. Bronley-DeLancey, A.Y., McMillan, D.C., McMillan, J.M., Jollow, D.J., Mohr, L.C. and Hoel, D.G. (2006). Application of cryopreserved human hepatocytes in trichloroethylene risk assessment: relative disposition of chloral hydrate to trichloroacetate and trichloroethanol. Environ. Health Perspect. 114, 1237-1242
  3. Bowman, Z.S., Morrow, J.D., Jollow, D.J. and McMillan, D.C. (2005). Primaquine-induced hemolytic anemia: Role of membrane lipid peroxidation and cytoskeletal protein alterations in the hemotoxicity of 5-hydroxyprimaquine. J. Pharmacol. Exp. Ther. 314,838-845
  4. Bowman, Z.S., Jollow, D.J. and McMillan, D.C. (2005). Primaquine-induced hemolytic anemia: Role of splenic macrophages in the fate of 5-hydroxyprimaquine-treated rat erythrocytes. J. Pharmacol. Exp. Ther. 315, 980-986
  5. McMillan, D.C., Powell, C.L., Bowman, Z.S. Morrow, J.D., and Jollow, D.J. (2005). Lipids vs. proteins as major targets of pro-oxidant, direct-acting hemolytic agents. Toxicol. Sci. 8, 274-283

Dr. McMillan's biographical information
return to top of page